These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37832541)

  • 1. Universal cell donor lines: A review of the current research.
    Simpson A; Hewitt AW; Fairfax KA
    Stem Cell Reports; 2023 Nov; 18(11):2038-2046. PubMed ID: 37832541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CRISPR/Cas9 Ribonucleoprotein Complex-Mediated Efficient B2M Knockout in Human Induced Pluripotent Stem Cells (iPSCs).
    Thongsin N; Wattanapanitch M
    Methods Mol Biol; 2022; 2454():607-624. PubMed ID: 33945142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering.
    Jang Y; Choi J; Park N; Kang J; Kim M; Kim Y; Ju JH
    Exp Mol Med; 2019 Jan; 51(1):1-11. PubMed ID: 30617277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of universal human embryonic stem cell lines.
    Kong M; Zhou D
    Immunol Lett; 2021 Feb; 230():59-62. PubMed ID: 33309828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
    Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
    J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Universal and hypoimmunogenic pluripotent stem cells for clinical usage.
    Sung TC; Maitiruze K; Pan J; Gong J; Bai Y; Pan X; Higuchi A
    Prog Mol Biol Transl Sci; 2023; 199():271-296. PubMed ID: 37678974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy.
    Mattapally S; Pawlik KM; Fast VG; Zumaquero E; Lund FE; Randall TD; Townes TM; Zhang J
    J Am Heart Assoc; 2018 Dec; 7(23):e010239. PubMed ID: 30488760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine.
    Trionfini P; Romano E; Varinelli M; Longaretti L; Rizzo P; Giampietro R; Caroli A; Aiello S; Todeschini M; Casiraghi F; Remuzzi G; Benigni A; Tomasoni S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients.
    Deuse T; Hu X; Gravina A; Wang D; Tediashvili G; De C; Thayer WO; Wahl A; Garcia JV; Reichenspurner H; Davis MM; Lanier LL; Schrepfer S
    Nat Biotechnol; 2019 Mar; 37(3):252-258. PubMed ID: 30778232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility.
    Xu H; Wang B; Ono M; Kagita A; Fujii K; Sasakawa N; Ueda T; Gee P; Nishikawa M; Nomura M; Kitaoka F; Takahashi T; Okita K; Yoshida Y; Kaneko S; Hotta A
    Cell Stem Cell; 2019 Apr; 24(4):566-578.e7. PubMed ID: 30853558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise Review: One Stone for Multiple Birds: Generating Universally Compatible Human Embryonic Stem Cells.
    Zheng D; Wang X; Xu RH
    Stem Cells; 2016 Sep; 34(9):2269-75. PubMed ID: 27251112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haplobanking induced pluripotent stem cells for clinical use.
    Sullivan S; Fairchild PJ; Marsh SGE; Müller CR; Turner ML; Song J; Turner D
    Stem Cell Res; 2020 Dec; 49():102035. PubMed ID: 33221677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of B2M bi-allelic knockout human induced pluripotent stem cells (MUSIi001-A-1) using a CRISPR/Cas9 system.
    Thongsin N; Wattanapanitch M
    Stem Cell Res; 2021 Oct; 56():102551. PubMed ID: 34628247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies.
    Alelign T; Ahmed MM; Bobosha K; Tadesse Y; Howe R; Petros B
    J Immunol Res; 2018; 2018():5986740. PubMed ID: 29693023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells.
    Suárez-Alvarez B; Rodriguez RM; Calvanese V; Blanco-Gelaz MA; Suhr ST; Ortega F; Otero J; Cibelli JB; Moore H; Fraga MF; López-Larrea C
    PLoS One; 2010 Apr; 5(4):e10192. PubMed ID: 20419139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do human leukocyte antigen-typed cellular therapeutics based on induced pluripotent stem cells make commercial sense?
    Bravery CA
    Stem Cells Dev; 2015 Jan; 24(1):1-10. PubMed ID: 25244598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9 immune-evasive hESCs are rejected following transplantation into immunocompetent mice.
    Frederiksen HR; Glantz A; Vøls KK; Skov S; Tveden-Nyborg P; Freude K; Doehn U
    Front Genome Ed; 2024; 6():1403395. PubMed ID: 38863835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-Cell Mediated Immune Rejection of Beta-2-Microglobulin Knockout Induced Pluripotent Stem Cell-Derived Kidney Organoids.
    Gaykema LH; van Nieuwland RY; Lievers E; Moerkerk WBJ; de Klerk JA; Dumas SJ; Kers J; Zaldumbide A; van den Berg CW; Rabelink TJ
    Stem Cells Transl Med; 2024 Jan; 13(1):69-82. PubMed ID: 37843402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen Presentation by Individually Transferred HLA Class I Genes in HLA-A, HLA-B, HLA-C Null Human Cell Line Generated Using the Multiplex CRISPR-Cas9 System.
    Hong CH; Sohn HJ; Lee HJ; Cho HI; Kim TG
    J Immunother; 2017; 40(6):201-210. PubMed ID: 28604557
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.